O60674 (JAK2_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase JAK2 UniProtKBInterProSTRINGInteractive Modelling

1132 aa; Sequence (Fasta)

Available Structures

162 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Structure of human JAK2 FERM/SH2 in complex with Erythropoietin Receptor Heteromer
P19235;
36-514
100.0
Structure of human JAK2 FERM/SH2 in complex with Leptin Receptor Heteromer
P48357;
38-514
100.0SO4;
Crystal Structure of the E372K LNK SH2 Domain mutant in Complex with a JAK2 pY813 Phosphopeptide Heteromer
O09039;
811-818
100CL;
Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with a JAK2 activation loop phospho… Heteromer
P18031;
1005-1010
100TRS;EDO;CL;NA;
Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with monophosphorylated JAK2 activa… Heteromer
P18031;
1005-1010
100TRS;
Crystal structure of PTP1B D181A/Q262A phosphatase domain with JAK2 activation loop phosphopeptide Heteromer
P18031;
1006-1010
100PO4;
Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with JAK2 activation loop phosphope… Heteromer
P18031;
1005-1009
100TRS;
X-ray co-crystal structure of compound 27 in with complex JAK2homo-2-mer842-1130
99.28YT8;
The crystal structure of JAK2 in complex with Compound 31homo-2-mer842-1130
99.29YT0;DMS;EDO;
JAK2 crystal structure in complex with Compound 13homo-2-mer843-1131
98.93YSI;EDO;
Crystal structure of JAK2 JH2-K539Lhomo-2-mer536-810
98.52ATP;MG;GOL;
Crystal Structure of the FERM-SH2 Domains of Jak2monomer37-514
100.0
JAK2 kinase (JH1 domain) in complex with compound 9monomer833-1132
1001K3;GOL;
JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL…monomer833-1132
1000X5;
Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that…monomer833-1130
100.09ZS;
JAK2 kinase (JH1 domain) triple mutant in complex with compound 12monomer835-1132
98.990NV;
JAK2 kinase (JH1 domain) in complex with compound 30monomer835-1132
1000NH;
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-114.monomer839-1132
100Y5D;
Crystal structure of JAK2 JH1 in complex with momelotinibmonomer840-1132
100C87;MLI;
Crystal structure of JAK2 JH1 in complex with ilginatinibmonomer840-1132
100S59;DMS;
Crystal structure of JAK2 JH1 in complex with cerdulatinibmonomer840-1132
100S5I;
Crystal structure of JAK2 JH1 in complex with gandotinibmonomer840-1132
100QQC;
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-150.monomer840-1132
100.0EDO;Y5G;
Crystal structure of JAK2 JH1 in complex with pacritinibmonomer840-1132
1006T3;
Crystal structure of JAK2 JH1 in complex with lestaurtinibmonomer840-1132
1002V9;
Fragment based discovery of JAK-2 inhibitorsmonomer839-1131
1005B3;
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitorsmonomer839-1131
100953;GOL;
Crystal structure of JAK2 JH1 in complex with itacitinibmonomer840-1132
100S4R;
Fragment based discovery of JAK-2 inhibitorsmonomer839-1131
1005B1;
JAK2 kinase (JH1 domain) triple mutant in complex with compound 7monomer840-1132
98.960NU;
Structure of Janus kinase 2 with a pyrrolotriazine inhibitormonomer840-1132
100J2I;
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to YM2-059monomer839-1130
100.04LY;
JAK2 kinase (JH1 domain) in complex with the inhibitor TRANS-4-[(8AS)-2-[(1R)-1-HYDROXYETHYL]IMIDAZ…monomer841-1132
1001J5;
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to type-II inhibitor BBT5…monomer839-1130
100.0046;EDO;
JAK2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenolmonomer840-1131
99.319I5;
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitorsmonomer839-1130
100.0GOL;VVQ;
JAK2 in complex with 4-{8-methoxy-2-[(1-methyl-1H-pyrazol-4-yl)amino]quinazolin-6-yl}phenolmonomer840-1131
99.319I8;
Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitormonomer840-1131
100DQX;
JAK2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2S)-1-hydroxypropan-2-yl]amino}quin…monomer840-1131
99.319HR;
Fragment based discovery of JAK-2 inhibitorsmonomer840-1131
1005B2;
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disordersmonomer840-1131
100.0QUP;
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…monomer841-1132
98.927GT;
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…monomer841-1132
99.317GY;
JAK2 JH1 in complex with JNJ-7706621 (Crystal Form 2)monomer840-1131
100.0SKE;
Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitormonomer841-1132
100.017P;
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…monomer841-1131
99.317GS;
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)…monomer842-1132
100.050V;
Triazolopyridine-based Inhibitor of Janus Kinase 2monomer842-1132
10088A;SO4;
JAK2 JH1 in complex with JNJ-7706621monomer840-1130
100.0SKE;SO4;GOL;
JAK2 JH1 in complex with MA9-086monomer841-1131
100R6S;
JAK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDEmonomer840-1130
1000X2;
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…monomer841-1131
99.317GX;
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL…monomer842-1132
100.050W;
JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209monomer842-1132
99.65CL;ZN;1M3;
Human JAK2 JH1 domain in complex with Baricitinibmonomer843-1132
100.0EDO;3JW;
Human JAK2 JH1 domain in complex with Ruxolitinibmonomer843-1132
100.0EDO;RXT;
JAK2 JH1 in complex with PN4-014monomer842-1131
100R5S;
Fragment-based discovery of 6-arylindazole JAK inhibitorsmonomer841-1130
99.316DP;
The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibit…monomer843-1132
99.65IZA;
Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitormonomer842-1131
100.0NVB;
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…monomer843-1132
99.287GV;
JAK2 kinase (JH1 domain) in complex with compound 8monomer843-1132
100.015V;
Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable…monomer843-1132
100JAK;
Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634monomer843-1132
99.652HB;
Crystal structures of JAK1 and JAK2 inhibitor complexesmonomer843-1132
99.65MI1;
Co-crystal structure of jak2 with thienopyridine 8monomer843-1132
100.00TP;
JAK2 kinase (JH1 domain) in complex with TG101209monomer843-1132
100.01M3;
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]…monomer842-1131
100.050O;
Crystal structure of JAK2 kinase domain in complex with compound 30monomer842-1131
100OV0;
Structure determination of Aurora Kinase in complex with inhibitormonomer843-1132
99.65L0I;
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITORmonomer842-1131
100.04OK;
Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for th…monomer843-1132
98.947GZ;
Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable…monomer843-1132
1001RS;
co-crystal structure of Jak2 with thienopyridine 19monomer843-1132
100.06TP;
Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1monomer843-1131
100.0I6C;GOL;
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitorsmonomer842-1130
100.0BJG;
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…monomer842-1130
100.04HZ;
Crystal Structure of JAK2 in complex with compound 25monomer843-1131
99.31D7D;
JAK2 JH1 in complex with baricitinibmonomer843-1131
1003JW;
JAK2 JH1 in complex with ruxolitinibmonomer843-1131
100RXT;
JAK2 in complex with 4-(2-amino-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluo…monomer843-1131
99.319I2;GOL;
Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivitymonomer842-1130
98.62QZ8;
JAK2 JH1 in complex with PN4-073monomer843-1131
100RXT;
JAK2 JH1 in complex with BL2-057monomer843-1131
100R6V;
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…monomer842-1130
100467;
JAK2 JH1 in complex with PN3-115monomer843-1131
100R61;
Janus Kinase 2 Inhibitorsmonomer842-1130
100.0JZH;NA;
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2monomer842-1130
100.01P6;
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…monomer842-1130
100.04HW;
JAK2 JH1 in complex with BL2-084monomer843-1131
100R6P;
JAK2 JH1 in complex with SY5-103monomer843-1131
100R5Y;
A Novel Chemotype of Kinase Inhibitorsmonomer842-1130
100.03KC;
JAK2 JH1 in complex with BL2-096monomer843-1131
100R6V;
JAK2 JH1 in complex with Fedratinibmonomer843-1131
1002TA;
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)…monomer843-1131
100.050Y;
JAK2 JH1 in complex with PN2-123monomer843-1131
100XZS;
JAK2 JH1 in complex with SG3-179monomer843-1131
1005W2;
JAK2 JH1 in complex with BL2-110monomer843-1131
100RG4;
JAK2 JH1 in complex with PN2-118monomer843-1131
100R6M;
Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 3monomer844-1132
100.0U8P;GOL;
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…monomer842-1130
100.0VJK;
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2monomer842-1130
100.01P5;
Crystal structure of JAK2 with Compound 11monomer843-1130
99.64UWP;
Aminoalkylpyrimidine Inhibitor Complexes with JAK2monomer841-1128
99.653O4;
Aminoalkylpyrimidine Inhibitor Complexes with JAK2monomer841-1128
99.65O19;
Inhibitors of Jak2 Kinase domainmonomer843-1130
99.28AZ5;
Crystal structure of JAK2 in complex with peficitinibmonomer843-1130
99.299T6;
Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594monomer843-1129
100.0046;MLI;
Inhibitors of Jak2 Kinase domainmonomer844-1130
98.91LMM;ACT;
Inhibitors of Jak2 Kinase domainmonomer844-1130
98.91F9J;ACE;
Inhibitors of Jak2 Kinase domainmonomer844-1130
98.91XWW;ACT;
Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 4monomer849-1132
100.0U8J;TRS;EDO;
Crystal structure of JAK2 JH2 in complex with Bemcentinibmonomer536-812
98.92Q8U;GOL;
Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATPmonomer537-812
98.17ATP;MG;GOL;
Crystal structure of JAK2 JH2-V617F in complex with Z902-A1monomer536-810
98.55GOL;ACT;Q9X;
JAK2-JH2monomer536-810
98.9136H;
Crystal structure of JAK2 JH2-V617F in complex with Z902-A3monomer536-809
98.91GOL;Q7F;
Crystal structure of JAK2 JH2-V617F in complex with HTS-A3monomer536-809
98.54GOL;T7I;
Crystal structure of JAK2 JH2 in complex with Z902-A3monomer536-809
98.91Q7F;GOL;
Crystal structure of JAK2 JH2-V617F in complex with CB76monomer536-809
98.91GOL;Q8N;
Crystal structure of JAK2 JH2-V617F in complex with JNJ-7706621monomer536-809
98.91GOL;SKE;
Crystal structure of JAK2 JH2-V617F in complex with Reversinemonomer536-809
98.91GOL;AD5;
Crystal structure of JAK2 JH2-R683Smonomer536-809
98.54GOL;T7I;
Crystal structure of the Jak2 pseudokinase domain (Mg-ATP-bound form)monomer536-809
98.91ATP;MG;ACT;
Crystal structure of the Jak2 pseudokinase domain mutant V617F (Mg-ATP-bound form)monomer536-809
98.91ATP;MG;
Crystal structure of JAK2 JH2-V617F in complex with Cdk2 inhibitor IVmonomer536-809
98.54GOL;AQG;
Crystal structure of the Jak2 pseudokinase domain (apo form)monomer536-809
98.91GOL;
JAK2 Pseudokinase in complex with NU6140monomer536-809
98.91AQG;
JAK2 JH2 IN COMPLEX WITH JAK292monomer536-809
98.91E8I;GOL;
Crystal structure of JAK2 JH2-V617F in complex with Bemcentinibmonomer536-809
98.54Q8U;
JAK2 Pseudokinase in complex with AZD7762monomer536-809
98.91YDJ;
JAK2 Pseudokinase in complex with JNJ7706621monomer536-809
98.91SKE;
JAK2 Pseudokinase in complex with AT9283monomer536-809
98.9135R;
JAK2 Pseudokinase in complex with BI-D1870monomer536-809
98.91584;
JAK2 JH2 in complex with PRT062607monomer536-808
98.9GOL;3YT;ACT;
JAK2 JH2 in complex with diaminopyrimidine JAK040monomer536-808
98.9J9D;GOL;DMS;
Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with CDK2-IVmonomer536-808
98.9AQG;
Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with HTSA3monomer536-808
98.53Q2Q;GOL;
JAK2 JH2 in complex with NVP-BSK805monomer537-809
98.9DQX;GOL;DMS;
JAK2 JH2 IN COMPLEX WITH JAK315monomer536-808
98.9E3W;GOL;
JAK2 Pseudokinase V617F in complex with AT9283monomer536-808
98.5335R;
Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with Reversinemonomer537-808
98.9AD5;GOL;
JAK2 JH2 in complex with IKK-2 Inhibitor VImonomer537-808
98.9IK1;GOL;ACT;
JAK2 JH2 in complex with 63552444monomer537-808
98.9E4V;GOL;
Crystal Structure of JAK2-V617F pseudokinase domain in complex with Compound 2monomer537-808
98.53EKT;EDO;
JAK2 JH2 in complex with a diaminopyrimidinemonomer537-808
98.98MY;GOL;DMS;ACT;
JAK2 JH2 in complex with JAK179monomer537-808
98.9GOL;M4G;
JAK2 JH2 in complex with JAK020monomer537-808
98.9GOL;VPJ;
Crystal structure of JAK2 JH2-I559Fmonomer538-809
98.53
JAK2 JH2 in complex with GLPG0634monomer537-808
98.9GOL;2HB;ACT;DMS;
JAK2 JH2 in complex with JAK170monomer537-808
98.9M3Y;
JAK2 JH2 in complex with JAK249monomer537-808
98.9DVY;
JAK2 JH2 in complex with JAK146monomer537-808
98.9M3A;
JAK2 JH2 in complex with BI-D1870monomer537-808
98.9GOL;7DZ;
JAK2 JH2 in complex with JAK190monomer537-808
98.88GOL;M57;
JAK2 JH2 in complex with XMU-MP-1monomer537-808
98.95BS;GOL;ACT;
JAK2 JH2 in complex with JAK168monomer537-808
98.9M4P;
JAK2 JH2 in complex with NU6102monomer537-808
98.89GOL;4SP;
JAK2 JH2 in complex with AT9283monomer537-808
98.9GOL;35R;ACT;DMS;
JAK2 JH2 in complex with JNJ-7706621monomer537-808
98.9SKE;GOL;DMS;
JAK2 JH2 in complex with JAK064monomer539-808
98.89VPS;GOL;
JAK2 JH2 in complex with JAK067monomer539-807
98.87V4D;

9 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6e2p.1.Amonomer0.8138-514
100.00
4oli.1.Amonomer0.71535-1130
46.90
4fl3.1.Amonomer0.59396-811
MG;24.81
1fmk.1.Amonomer0.58397-811
26.09
1y57.1.Amonomer0.58397-811
26.09
1opl.2.Amonomer0.56397-811
25.07
4xi2.1.Amonomer0.55396-810
24.86
2j0j.1.Amonomer0.50146-811
23.00
2j0k.1.Amonomer0.5062-811
21.96